Royal Marsden researchers gain academic promotions

Six Royal Marsden clinicians have been awarded the titles by The Institute of Cancer Research, London.

The Royal Marsden clinicians who have received awards

From left to right: Dr Kate Newbold, Mr Andrew Hayes, Dr Samra Turajlic, Dr Anna Kirby, Dr Christina Messiou and Dr Julia Chisholm

Congratulations to six Royal Marsden clinicians who have been awarded the titles of Professor and Reader by our academic partner The Institute of Cancer Research, London.

Consultant Radiologist Christina Messiou, Consultant Medical Oncologist Samra Turajlic and Consultant Surgeon Andrew Hayes all gain the title of Professor.

Consultant Paediatric Oncologist Julia Chisholm, Consultant Clinical Oncologist Anna Kirby and Consultant Clinical Oncologist Kate Newbold all gain the title of Reader.

The new titles acknowledge their contribution to the work of academic excellence, teaching and leadership. The new titles officially start from 1 October 2022.

Professor David Cunningham, Director of Clinical Research at The Royal Marsden, said: “I am extremely pleased for all who received their academic titles from the ICR.

“The Professor and Reader titles really reflect the breadth of research and teaching these consultants carry out for the benefit of all cancer patients on top of their clinical commitments every day.”

Mr Hayes, who specialises in the surgery of soft tissue sarcoma, malignant melanoma and other rare tumours of the skin and soft tissue, said: “I am absolutely delighted to have been awarded a Professorship by the ICR for the research I have undertaken in the fields of Sarcoma and Skin Cancer. I am hugely indebted to all of my PhD students who have worked with me over the last decade and to all of my scientific collaborators both at The Royal Marsden and the ICR. I am really looking forward to continuing this research to improve the treatments we have for patients with sarcoma and skin cancer.” 

Dr Turajlic, who is specialises in the treatment of kidney cancer and melanoma with novel therapies, said: “I’m delighted with this recognition and would like to thank all my colleagues at The Royal Marsden, The Crick and the ICR for their support.”